Purpose: To explore ovarian cancer survivors’ symptom experience of cancer-related cognitive impairment (CRCI). Methods: Semi-structured interviews were conducted with eligible ovarian cancer patients in Cancer Center of Fudan University, Shanghai, China. This study was guided by symptom management theory. Qualitative content analysis and thematic framework analysis were used to refine themes.Results: The average age of participants (n=34) was 51.38 years (range 25-65 years)and median time since diagnosis was one year(range 0.2-42.8 years).Three themes and nine subthemes were identified from the research. For perception of cognitive changes: Become stupid, not as smart as before; not noticing/ having the chance to notice any cognitive change. Possible influence events in the evaluation of CRCI: comfortable, monotonous, isolation and narrow-focused life cause the brain to "retire”; surgical anesthesia, chemotherapy as well as fatigue, sleep disorders and anxiety were also blamed for the change. For the impact of CRCI in the evaluation of cognitive changes: it was not an issue for most participants and they didn’t particularly care, only a few said that their self-confidence was affected a little. For responses to cognitive decline: Trying not burden brain, actively or passively let themselves “slow down" or "offload" things. Personalized and repeated "note", "check" and "confirm" measures to prevent mistakesConclusion: The majority of ovarian cancer patients experienced symptoms of CRCI, highlighted by memory and attention problems, however most patients stated that cognitive symptoms didn’t affect their lives. Sociocultural and cancer copying style played an important role in the CRCI symptom experience.
Background: Immunetherapy has emerged as a novel therapy, while many patients are refractory. Although, several biomarkers have been identifed as predictive biomarkers for immunotherapy, such as umor specific genes, PD-1/PD-L1, tumor mutation burn (TMB), and microsatellite instability (MSI), results remain unsatsficatiory. We investigated the characteristics of low-density lipoprotein receptor-related protein 2 (LRP2) mutation in the cancer genome atlas (TCGA) and explored the potential association of LRP2 mutation with immunotherapy. Methods: Characteristic of LRP2 mutation in 33 cancer types was analyzed using large-scale public data. The association of LRP2 mutation with immune cell infiltration and immunotherapy efficacy was evaluated. Finally, a LPR2 mutation signature (LMS) was developed and validated by TCGA-UCEC and pan-cancer cohorts. Furthermore, we demonstrated the predictive power of LMS score in independent immunotherapy cohorts by perfoming a meta-analysis. Results: Our results revealed that patients with LRP2 mutant had higher TMB and MSI compared with patients without LRP2 mutation. Meanwhile, LRP2 mutation was associated with higher infiltration level of immune cells and higher expression of immune-related genes and signaling pathways. Patients with LRP2 mutation presented long overall survival (OS) after immunotherapy. In endothelial cancer (EC), patients with LRP2 mutation belonged to the POLE and MSI-H type of EC molecular types, with a better prognosis. Finally, we developed a LRP2 mutation signature (LMS), that was significantly associated with prognosis in patients receiving immunotherapy. Conclusion: These results indicated that LRP2 mutation can serve as a biomarker for the personalization of cancer immunotherapy. Importantly, LMS is a potential predicator of patients prognosis after immunotherapy.
Purpose Immunotherapy has emerged as a novel therapy, while many patients are refractory. Although, several biomarkers have been identified as predictive biomarkers for immunotherapy, such as tumor specific genes, PD-1/PD-L1, tumor mutation burn (TMB), and microsatellite instability (MSI), results remain unsatisfactory.Methods We investigated the characteristics of low-density lipoprotein receptor-related protein 2 (LRP2) mutation in the cancer genome atlas (TCGA) and explored the potential association of LRP2 mutation with immunotherapy. Characteristic of LRP2 mutation in 33 cancer types was analyzed using large-scale public data. The association of LRP2 mutation with immune cell infiltration and immunotherapy efficacy was evaluated. Finally, a LPR2 mutation signature (LMS) was developed and validated by TCGA-UCEC and pan-cancer cohorts. Furthermore, we demonstrated the predictive power of LMS score in independent immunotherapy cohorts by performing a meta-analysis.Results Our results revealed that patients with LRP2 mutant had higher TMB and MSI compared with patients without LRP2 mutation. Meanwhile, LRP2 mutation was associated with higher infiltration level of immune cells and higher expression of immune-related genes and signaling pathways. Patients with LRP2 mutation presented long overall survival (OS) after immunotherapy. In endothelial cancer (EC), patients with LRP2 mutation belonged to the POLE and MSI-H type of EC molecular types, with a better prognosis. Finally, we developed a LRP2 mutation signature (LMS), that was significantly associated with prognosis in patients receiving immunotherapy.Conclusion These results indicated that LRP2 mutation can serve as a biomarker for the personalization of cancer immunotherapy. Importantly, LMS is a potential predictor of patients prognosis after immunotherapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.